Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Licenses Probe Technologies to Celera Diagnostics

NEW YORK, Feb. 10 (GenomeWeb News) - Epoch Biosciences has licensed two DNA probe technologies to Celera Diagnostics, the company said today.


Under the worldwide non-exclusive license, Celera can manufacture, sell, and distribute TaqMan probes that use Epoch's MGB minor groove binder and Eclipse Dark quencher technologies in diagnostics products for infectious diseases. In exchange, Epoch will receive license fees and royalties on sales of these products.


According to Bothell, Wash.-based Epoch, this is its first deal in the human diagnostics area.



The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.